Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China

ConclusionIn conclusion, 1q21 gain is an adverse prognostic factor for MM patients received ASCT.

Source: Cancer Medicine - September 1, 2020 Category: Cancer & Oncology Authors: Wen Gao, Yuan Jian, Juan Du, Xiaozhe Li, Huixing Zhou, Zhiyao Zhang, Guangzhong Yang, Guorong Wang, Ying Tian, Yanchen Li, Yin Wu, Weijun Fu, Juan Li, Wenming Chen Tags: ORIGINAL RESEARCH Source Type: research